COMPLETE RESEARCH GUIDEPEPTIDE PEN
Tirzepatide
Dual Incretin Research Peptide
>99%20 mgFROM EUR 169POPULAR
QUICK ANSWER
Tirzepatide (dual incretin research peptide) is a >99% purity research compound. A dual GIP/GLP-1 receptor agonist extensively studied in metabolic research. Clinical trials suggest Tirzepatide may modulate appetite signalling and glucose homeostasis through dual incretin pathways. ORYN delivers Tirzepatide in a precision-dosed reusable pen starting from EUR 169. All products are for research purposes only.
Science & Research
FULL ENCYCLOPEDIA ENTRY →MOLECULAR PROFILE
FORMULA
C225H348N48O68
WEIGHT
4813.45 Da
CLASSIFICATION
Dual GIP/GLP-1 Receptor Agonist (Incretin Mimetic)
STUDIES CITED
4 key studies
Mechanism of Action
Tirzepatide represents a paradigm shift in metabolic peptide science as the first dual GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptor agonist. By activating both incretin pathways simultaneously, it produces metabolic effects that exceed what either pathway achieves alone.
READ FULL MECHANISM →Key Published Studies
2021
SURPASS-2: Tirzepatide versus semaglutide in patients with type 2 diabetes
Tirzepatide demonstrated superior HbA1c reduction vs. semaglutide 1mg, with significantly greater weight loss at all three dose levels.
2022
SURMOUNT-1: Tirzepatide for treatment of obesity
72-week treatment achieved 22.5% mean weight reduction at the 15mg dose in participants with obesity, the highest ever recorded for a pharmaceutical agent.
2020
Dual GIP/GLP-1 receptor agonism: mechanisms and metabolic effects
Characterised the synergistic metabolic benefits of dual incretin activation, including enhanced insulin sensitivity, fat metabolism, and appetite regulation.
2023
SURMOUNT-4: Sustained weight loss maintenance with tirzepatide
Demonstrated that continued tirzepatide treatment maintained weight loss over 88 weeks, while discontinuation led to significant regain, underscoring the importance of sustained treatment.
Research History
Tirzepatide was developed by Eli Lilly and Company, building on decades of incretin biology research. The concept of dual incretin receptor agonism emerged from observations that GIP and GLP-1 activate complementary metabolic pathways, and that simultaneous activation might produce synergistic benefits.
FULL RESEARCH HISTORY →ORYN Tirzepatide Product
PEPTIDE PENPOPULAR
Tirzepatide — Dual Incretin Research Peptide
A dual GIP/GLP-1 receptor agonist extensively studied in metabolic research. Clinical trials suggest Tirzepatide may modulate appetite signalling and glucose homeostasis through dual incretin pathways. ORYN Tirzepatide pen delivers 20mg/3ml in a reusable system with precision dosing for 30 days.
PURITY
>99%
FILL VOLUME
3 mL
DOSAGE
10 mg
FORMULATION
Pharma Grade
DOSING PERIOD
30 Days
STERILIZATION
0.22um Filter + Gamma Ray
EUR 169VIEW PRODUCT DETAILS
Articles & Guides
ALL ARTICLES →LEGAL & COMPLIANCE
Are Peptides Legal in the UK? Complete 2026 Guide
Understanding the legal landscape of research peptides in the United Kingdom. What you need to know about purchasing, possessing, and using peptides in 2026.
8 min read
PEPTIDE RESEARCH
Tirzepatide vs Semaglutide: Comparing Weight Loss Peptides
A comprehensive comparison of two leading metabolic peptides — tirzepatide's dual GIP/GLP-1 action versus semaglutide's GLP-1 approach.
7 min read
PEPTIDE RESEARCH
Best Peptides for Weight Loss in the UK (2026)
A comprehensive guide to the leading metabolic and weight-loss peptides available for research in the UK. Compare mechanisms, efficacy data, and delivery systems.
9 min read
BUYING GUIDES
Best Peptide Pens UK 2026: Complete Buyer's Guide
A comprehensive comparison of the best peptide pen systems available in the UK market for 2026, including ORYN, PharmaLabGlobal, and other leading suppliers.
12 min read
BUYING GUIDES
How to Buy Peptides Online in the UK: 2026 Definitive Guide
Your complete guide to safely purchasing research peptides online in the UK, including how to verify quality, spot scams, and choose the right supplier.
9 min read
PRODUCT GUIDES
Tirzepatide Pen UK: Complete Research Guide 2026
Everything UK researchers need to know about tirzepatide peptide pens: mechanism of action, dosing, ORYN's dual pen options, and how it compares to semaglutide.
10 min read
Head-to-Head Comparisons
ALL COMPARISONS →COMPARISON
Tirzepatide vs Semaglutide: Which Weight Loss Peptide Is Superior?
TirzepatideVSMediT Pen
Clinical data consistently shows tirzepatide's dual GIP/GLP-1 mechanism produces greater weight reduction than semaglutide's GLP-1-only approach. ORYN offers tirzepatide in two formats: the standard pen (10mg, €169) and the MediT prefilled pen (40mg, €249).
COMPARISON
Tirzepatide 10mg Pen vs 40mg MediT: Which Format Is Right?
TirzepatideVSMediT Pen
Both formats deliver the same pharmaceutical-grade tirzepatide with >99% purity. The Tirzepatide Pen (10mg, €169) offers maximum dosing flexibility for titration and dose-finding research. The MediT Pen (40mg, €249) offers maximum convenience with once-weekly fixed-dose administration. Your choice depends on whether flexibility or simplicity is more important for your research protocol.
COMPARISON
Ipamorelin vs Tirzepatide: Growth Hormone vs Metabolic Peptide
IpamorelinVSTirzepatide
Ipamorelin and Tirzepatide are entirely different classes of peptide. Ipamorelin is a selective growth hormone secretagogue — ideal for research into GH-mediated effects like body composition, sleep, and recovery. Tirzepatide is a dual GIP/GLP-1 receptor agonist — the leading compound for metabolic and weight management research. The choice depends entirely on your research focus: growth hormone biology or metabolic science.
COMPARISON
CJC-1295 vs Semaglutide: Growth Hormone vs Weight Loss Peptide
CJC-1295VSTirzepatide
CJC-1295 and Semaglutide (compared here alongside Tirzepatide) serve entirely different purposes. CJC-1295 is a GHRH analogue for sustained growth hormone research — body composition, recovery, sleep, and anti-ageing. Semaglutide and Tirzepatide are incretin-based compounds for metabolic and weight management research. ORYN offers CJC-1295 for GH protocols and Tirzepatide (which surpasses Semaglutide in clinical data) for metabolic protocols.
COMPARISON
Peptide Pen vs MediT Pen: Multi-Dose Daily vs Prefilled Weekly
TirzepatideVSMediT Pen
The Peptide Pen and MediT Pen represent two distinct delivery philosophies. The Peptide Pen system offers maximum dosing flexibility with daily precision control across 8 peptide compounds. The MediT Pen offers maximum convenience with prefilled, once-weekly dosing. Both use pharmaceutical-grade compounds with >99% purity — the choice comes down to whether your protocol benefits more from flexibility or simplicity.
COMPARISON
Tirzepatide vs CJC-1295 for Weight Management: Which Approach Works?
TirzepatideVSCJC-1295
For direct weight management research, Tirzepatide is overwhelmingly superior — clinical trials show 15-21% body weight reduction through dual GIP/GLP-1 receptor action. CJC-1295 supports body composition indirectly through sustained GH release, improving lean mass and fat metabolism. They represent fundamentally different approaches: Tirzepatide reduces weight through appetite and metabolic regulation, whilst CJC-1295 improves body composition through anabolic GH pathways.
COMPARISON
Tirzepatide vs NAD+: Two Approaches to Metabolic Research
TirzepatideVSNAD+
Tirzepatide and NAD+ address metabolism through entirely different mechanisms. Tirzepatide acts on incretin receptors (GIP/GLP-1) to regulate appetite, insulin sensitivity, and body composition. NAD+ restores mitochondrial energy production and activates sirtuin longevity pathways. Tirzepatide is the stronger choice for weight and glycaemic research; NAD+ is superior for cellular energy and systemic aging endpoints.
COMPARISON
MediT Pen vs Standard Tirzepatide Pen: Which Format Fits Your Research?
MediT PenVSTirzepatide
The MediT prefilled pen (40 mg, EUR 249) offers maximum convenience with weekly dosing and 4x more tirzepatide per unit. The standard pen (10 mg, EUR 169) offers maximum flexibility with adjustable daily dosing. The MediT is better value per milligram (EUR 6.23/mg vs EUR 16.90/mg) and ideal for established protocols. The standard pen is ideal for dose-finding research or researchers who need precise daily adjustments.
Research Protocols
ALL PROTOCOLS →Frequently Asked Questions
FULL FAQ →What is tirzepatide and how is it different from semaglutide?
+
Tirzepatide is a dual GIP/GLP-1 receptor agonist — it activates both major incretin pathways simultaneously. Semaglutide is a GLP-1 receptor agonist only. Clinical trials show tirzepatide achieves greater weight loss (up to 22.5%) and superior glycaemic control compared to semaglutide, likely due to the synergistic effects of dual receptor activation.
What is the mechanism of action of tirzepatide?
+
Tirzepatide activates GIP and GLP-1 receptors simultaneously. GLP-1 pathway activation slows gastric emptying, reduces appetite, and enhances insulin release. GIP pathway activation improves insulin sensitivity in fat tissue and promotes fat metabolism. The combined effect produces metabolic benefits exceeding either pathway alone.
What clinical evidence supports tirzepatide?
+
The SURPASS trials demonstrated tirzepatide's superiority over semaglutide for diabetes management. The SURMOUNT trials showed 22.5% mean weight reduction at 15mg — the largest pharmacological weight loss ever recorded. Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity).
How does ORYN deliver tirzepatide?
+
ORYN offers two tirzepatide delivery systems: the Peptide Pen (10mg, 30-day precision dosing) and the MediT Pen (40mg prefilled, once-weekly single-use injection). Both are >99% purity and GMP manufactured. The MediT Pen is designed for convenience with pre-set weekly dosing.
What is Tirzepatide?
+
Tirzepatide is a synthetic peptide that acts as a dual agonist on both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual mechanism is unique among metabolic peptides and has been the subject of extensive clinical research. ORYN's Tirzepatide pen contains 10 mg at >99% purity.
How does Tirzepatide work?
+
Tirzepatide simultaneously activates GIP and GLP-1 receptors, which are involved in insulin secretion, glucose metabolism, appetite regulation, and gastric emptying. The dual-agonist mechanism is believed to produce synergistic metabolic effects beyond what single-receptor agonists achieve. Published clinical trials have documented significant outcomes in metabolic research endpoints.
What is Tirzepatide used for in research?
+
Tirzepatide is studied in research related to metabolic function, body weight regulation, insulin sensitivity, blood glucose control, appetite physiology, and cardiovascular metabolic health. It has been the subject of the SURPASS and SURMOUNT clinical trial programmes with published results in major peer-reviewed journals.
How is ORYN Tirzepatide administered?
+
ORYN Tirzepatide is available in a pre-mixed peptide pen containing 10 mg in 3 mL. The pen is designed for subcutaneous injection with precise click-based dosing. No manual reconstitution is required. The 30-day pen format allows for consistent daily dosing throughout the research period.
Explore More ORYN Products
RESEARCH PURPOSES ONLY. All content on this page is intended for informational and educational purposes for qualified researchers. ORYN products are not approved as medicines and are not intended for human therapeutic use. Do not use ORYN products for self-administration. Consult relevant regulations in your jurisdiction.